Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PRKCB | P05771 | 2/20 | 0.37 |
| ▸ | PRKCA | P17252 | 2/20 | 0.37 |
| ▸ | PRKCH | P24723 | 2/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL5206984 | 0.96 | KDM4E (0.39) | CYP4F2CYP4A11KDM4ELMNATSHR | |
| SCHEMBL3588780 | 0.92 | CYP4F2 (0.40) | CYP4F2CYP4A11KDM4ELMNATSHR | |
| SCHEMBL992003 | 0.82 | SLC6A4 (0.46) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL991440 | 0.81 | KDM4E (0.43) | KDM4ELMNAMAPTKMT2ATRPV1 | |
| SCHEMBL1028100 | 0.79 | HDAC1 (0.34) | CYP4F2CYP4A11KDM4ELMNAMAPT | |
| SCHEMBL991313 | 0.79 | PTGS2 (0.54) | KDM4ETSHRMAPTL3MBTL1HTR1A | |
| SCHEMBL989998 | 0.79 | KDM4E (0.41) | KDM4ELMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL2788047 | 0.78 | TSHR (0.42) | CYP4F2CYP4A11KDM4ELMNATSHR | |
| SCHEMBL27658425 | 0.78 | RAD52 (0.44) | CYP4F2CYP4A11TSHRPRKCBPRKCA | |
| SCHEMBL991950 | 0.77 | ALOX15 (0.40) | KDM4ELMNATSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | CYP4F2 3473/4885CYP4A11 2379/4885KDM4E 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.